

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Rainmed Medical Limited

潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2297)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE

This announcement is made by Rainmed Medical Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that Mr. Lau Tsz Ho Tony (“**Mr. Lau**”) has resigned as an independent non-executive Director with effect from August 15, 2023 due to the need to devote more time for his other commitments. Upon Mr. Lau’s resignation as an independent non-executive Director, he has ceased to be a member of the audit committee (the “**Audit Committee**”) of the Company with effect from the same date.

Mr. Lau has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Lau for his valuable contributions to the Group during his tenure of office in the Company.

(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The Board is pleased to announce that Mr. Chen Xuefeng (陳雪峰) (“**Mr. Chen**”) has been appointed as an independent non-executive Director and a member of the Audit Committee with effect from August 15, 2023.

The biographical details of Mr. Chen are set out below:

Mr. Chen Xuefeng (陳雪峰), aged 42, obtained a Bachelor of Laws degree from the Southwest University of Political Science and Law (西南政法大學) in the People's Republic of China (the "PRC") in July 2004. He further received the legal professional qualification certificate in the PRC in February 2007. Mr. Chen has been certified as a certified public accountant and a certified tax agent in the PRC since December 2015 and June 2011, respectively. Mr. Chen has profound experience in financing and investment. He served as an associate of Guangdong Jundao Law Firm* (廣東君道律師事務所) from April 2007 to October 2010 and as a partner of Guangdong Ruiting Law Firm* (廣東瑞霆律師事務所) from October 2010 to April 2012, from which he gained extensive experience in capital market. From April 2012 to April 2015, he served as a vice president of Shenzhen Jinxin Industrial Group Co., Ltd* (深圳市金信實業集團有限公司). Since September 2015, he has been a managing director and person in charge of the investment and financing management department of Shenzhen Tiantu Capital Management Center (Limited Partnership)* (深圳天圖資本管理中心 (有限合夥)), where he is responsible for fund management and project post-investment management.

Mr. Chen has entered into an appointment letter with the Company for a term commencing from August 15, 2023 until the next annual general meeting of the Company, upon which Mr. Chen shall be eligible for re-election by the shareholders of the Company. Thereafter, Mr. Chen will be subject to retirement by rotation and re-election in accordance with the memorandum and articles of association of the Company. Mr. Chen is entitled to a director's fee of HK\$280,000 per annum. The emolument of Mr. Chen has been determined by the Board with reference to the prevailing market conditions, his experience, his roles and responsibilities and the Company's remuneration policy. Such remuneration has been recommended by the Remuneration Committee of the Company and approved by the Board.

As at the date of this announcement, save as disclosed above, (i) Mr. Chen does not have any interests or short positions in any shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); (ii) Mr. Chen has not held any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) Mr. Chen does not have any relationship with any Directors, senior management or substantial shareholders of the Company (as defined under the Listing Rules); and (iv) Mr. Chen does not hold any other position in the Company and/or its subsidiaries.

Mr. Chen has confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules. Save as disclosed above, there is no other matter relating to his appointment as an independent non-executive Director that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange, and there is no other information that need to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Chen for joining the Board.

By Order of the Board
Rainmed Medical Limited
Huo Yunfei
Chairman of the Board and Executive Director

Hong Kong, August 15, 2023

As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Lyu Yonghui, Mr. Zhang Liang and Ms. Gu Yang as executive Directors, Mr. Wang Lin and Mr. Heng Lei as non-executive Directors, and Mr. Liu Shuen Kong, Mr. Li Ho Man and Mr. Chen Xuefeng as independent non-executive Directors.

** For identification purposes only*